Overview

Pharmacology of Adjuvant Hormonotherapy in Breast Cancer

Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is a biomedical study of interventional type, multicenter, inter-regional. Patients with hormono-depending breast cancer, for which an indication of adjuvant hormonotherapy treatment (according to the current treatments) was retained, will be enrolled in this study. The main objective is to estimate the correlations between pharmacokinetic and pharmacogenetic parameters of adjuvant hormonal breast cancer treatment, during the first 3 years.
Phase:
Phase 4
Details
Lead Sponsor:
Institut Claudius Regaud
Treatments:
Anastrozole
Exemestane
Letrozole
Tamoxifen